gliclazide sold brand name diamicron among others sulfonylurea type antidiabetic medication used treat type used dietary changes exercise weight loss taken side effect may include low blood sugar vomiting abdominal pain rash liver use significant kidney problems liver problems pregnant gliclazide sulfonylurea family works mostly increasing release gliclazide patented approved medical use world health organizations list essential available sale united gliclazide used control hyperglycemia gliclazideresponsive diabetes mellitus stable mild nonketosis prone type diabetes used diabetes controlled proper dietary management exercise metformin already national kidney foundation update claims gliclazide require dosage titration even end stage kidney disease common adverse effects uncommon adverse effect rare adverse effects hyperglycemic action may caused danazol chlorpromazine glucocorticoids progestogens agonists hypoglycemic action may potentiated phenylbutazone alcohol fluconazole Î²blockers possibly ace inhibitors found rifampin increases gliclazide metabolism humans gliclazide overdose may cause severe hypoglycemia requiring urgent administration glucose iv gliclazide selectively binds sulfonylurea receptors surface pancreatic betacells shown provide cardiovascular protection bind sulfonylurea receptors binding effectively closes k ion channels decreases efflux potassium cell leads depolarization cell causes voltage dependent ion channels open increasing influx calcium bind activate calmodulin turn leads exocytosis insulin vesicles leading insulin mouse model maturityonset diabetes young mody diabetes suggested reduced gliclazide clearance stands behind therapeutic success human mody patients urbanova et al found human mody patients respond differently consistent decrease gliclazide clearance randomly selected classification ambiguous literature uses sulfonylurea according biopharmaceutical classification system bcs gliclazide falls bcs class ii drug poorly soluble highly permeable water solubility needed gliclazide undergoes extensive metabolism several inactive metabolites human beings mainly methylhydroxygliclazide carboxygliclazide involved formation hydroxygliclazide human liver microsomes panel recombinant human pharmacokinetics gliclazide mr affected mainly genetic polymorphism instead genetic httpsenwikipediaorgwikigliclazide